综述 |
|
|
|
|
肠道菌群及其代谢产物与T2DM发病机制及干预措施* |
甘巧,孟庆雄**() |
昆明理工大学生命科学与技术学院 昆明 650504 |
|
Intestinal Microflora and Its Metabolites in Relation to the Pathogenesis and Intervention of T2DM |
GAN Qiao,MENG Qing-xiong**() |
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650504, China |
[1] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版). 中国实用内科杂志, 2018, 38(4):292-344.
|
|
Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China(2017 Edition). Chinese Journal of Practical Internal Medicine, 2018, 38(4):292-344.
|
[2] |
Chen L, Magliano D J, Zimmet P Z. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nature Reviews Endocrinology, 2012, 8(4):228-236.
doi: 10.1038/nrendo.2011.183
|
[3] |
Viigimaa M, Sachinidis A, Toumpourleka M, et al. Macrovascular complications of type 2 diabetes mellitus. Current Vascular Pharmacology, 2020, 18(2):110-116.
doi: 10.2174/1570161117666190405165151
pmid: 30961498
|
[4] |
Khan N U, Lin J, Liu X K, et al. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2020, 1868(10):140475.
doi: 10.1016/j.bbapap.2020.140475
|
[5] |
Amaefule C E, Sasitharan A, Kalra P, et al. The accuracy of haemoglobin A1c as a screening and diagnostic test for gestational diabetes: a systematic review and meta-analysis of test accuracy studies. Current Opinion in Obstetrics & Gynecology, 2020, 32(5):322-334.
|
[6] |
Luca M, Di Mauro M, Di Mauro M, et al. Gut microbiota in Alzheimer’s disease, depression, and type 2 diabetes mellitus: the role of oxidative stress. Oxidative Medicine and Cellular Longevity, 2019, 2019:4730539.
|
[7] |
Caesar R. Pharmacologic and nonpharmacologic therapies for the gut microbiota in type 2 diabetes. Canadian Journal of Diabetes, 2019, 43(3):224-231.
doi: 10.1016/j.jcjd.2019.01.007
|
[8] |
Morais L H, Schreiber H L, Mazmanian S K. The gut microbiota-brain axis in behaviour and brain disorders. Nature Reviews Microbiology, 2021, 19(4):241-255.
doi: 10.1038/s41579-020-00460-0
pmid: 33093662
|
[9] |
Wang R, Tang R Q, Li B, et al. Gut microbiome, liver immunology, and liver diseases. Cellular & Molecular Immunology, 2021, 18(1):4-17.
|
[10] |
Wang Z Y, Zeng M M, Wang Z J, et al. Dietary polyphenols to combat nonalcoholic fatty liver disease via the gut-brain-liver axis: a review of possible mechanisms. Journal of Agricultural and Food Chemistry, 2021, 69(12):3585-3600.
doi: 10.1021/acs.jafc.1c00751
|
[11] |
Fried S, Wemelle E, Cani P D, et al. Interactions between the microbiota and enteric nervous system during gut-brain disorders. Neuropharmacology, 2021, 197:108721.
doi: 10.1016/j.neuropharm.2021.108721
|
[12] |
Wang S Z, Yu Y J, Adeli K. Role of gut microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis. Microorganisms, 2020, 8(4):527.
doi: 10.3390/microorganisms8040527
|
[13] |
Pagliari D, Saviano A, Newton E E, et al. Gut microbiota-immune system crosstalk and pancreatic disorders. Mediators of Inflammation, 2018, 2018:7946431.
|
[14] |
Maranta F, Cianfanelli L, Cianflone D. Glycaemic control and vascular complications in diabetes mellitus type 2. Advances in Experimental Medicine and Biology, 2021, 1307:129-152.
|
[15] |
Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences, 2020, 21(17):6275.
doi: 10.3390/ijms21176275
|
[16] |
Merino B, Fernández-Díaz C M, Cózar-Castellano I, et al. Intestinal fructose and glucose metabolism in health and disease. Nutrients, 2019, 12(1):94.
doi: 10.3390/nu12010094
|
[17] |
Nilsson E, Matte A, Perfilyev A, et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. The Journal of Clinical Endocrinology & Metabolism, 2015, 100(11):E1491-E1501.
doi: 10.1210/jc.2015-3204
|
[18] |
Mazoochian L, Mohammad Sadeghi H M, Pourfarzam M. The effect of FADS2 gene rs174583 polymorphism on desaturase activities, fatty acid profile, insulin resistance, biochemical indices, and incidence of type 2 diabetes. Journal of Research in Medical Sciences, 2018, 23:47.
doi: 10.4103/jrms.JRMS_961_17
pmid: 29937909
|
[19] |
Fu S Y, Meng Y H, Zhang W L, et al. Transcriptomic responses of skeletal muscle to acute exercise in diabetic goto-kakizaki rats. Frontiers in Physiology, 2019, 10:872.
doi: 10.3389/fphys.2019.00872
|
[20] |
Volkov P, Bacos K, Ofori J K, et al. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis. Diabetes, 2017, 66(4):1074-1085.
doi: 10.2337/db16-0996
pmid: 28052964
|
[21] |
Taneera J, Fadista J, Ahlqvist E, et al. Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes. Molecular and Cellular Endocrinology, 2013, 375(1-2):35-42.
doi: 10.1016/j.mce.2013.05.003
pmid: 23707792
|
[22] |
García-Chapa E G, Leal-Ugarte E, Peralta-Leal V, et al. Genetic epidemiology of type 2 diabetes in Mexican mestizos. BioMed Research International, 2017, 2017:3937893.
|
[23] |
Engwa G A, Nwalo F N, Chikezie C C, et al. Possible association between ABCC8 C49620T polymorphism and type 2 diabetes in a Nigerian population. BMC Medical Genetics, 2018, 19(1):78.
doi: 10.1186/s12881-018-0601-1
|
[24] |
Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metabolism, 2019, 29(5):1028-1044.
doi: 10.1016/j.cmet.2019.03.009
|
[25] |
Koh A, Molinaro A, Ståhlman M, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell, 2018, 175(4):947-961, e17.
doi: 10.1016/j.cell.2018.09.055
|
[26] |
Pedersen H K, Gudmundsdottir V, Nielsen H B, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature, 2016, 535(7612):376-381.
doi: 10.1038/nature18646
|
[27] |
Ebrahimzadeh Leylabadlo H, Sanaie S, Sadeghpour Heravi F, et al. From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infection,Genetics and Evolution, 2020, 81:104268.
doi: 10.1016/j.meegid.2020.104268
|
[28] |
Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocrine Connections, 2016, 5(1):1-9.
doi: 10.1530/EC-15-0094
pmid: 26555712
|
[29] |
Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine, 2017, 23(7):850-858.
doi: 10.1038/nm.4345
|
[30] |
Amyot J, Semache M, Ferdaoussi M, et al. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-Like Receptor-4 and NF-κB signalling. PLoS One, 2012, 7(4):e36200.
doi: 10.1371/journal.pone.0036200
|
[31] |
Cani P D, Possemiers S, van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut, 2009, 58(8):1091-1103.
doi: 10.1136/gut.2008.165886
|
[32] |
Li B, Fang J, Zuo Z C, et al. Activation of porcine alveolar macrophages by Actinobacillus pleuropneumoniae lipopolysaccharide via the toll-like receptor 4/NF-κB-mediated pathway. Infection and Immunity, 2018, 86(3):e00642-17.
|
[33] |
Dey P. Gut microbiota in phytopharmacology: a comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. Pharmacological Research, 2019, 147:104367.
doi: 10.1016/j.phrs.2019.104367
|
[34] |
Chassaing B, Raja S M, Lewis J D, et al. Colonic microbiota encroachment correlates with dysglycemia in humans. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4(2):205-221.
doi: 10.1016/j.jcmgh.2017.04.001
pmid: 28649593
|
[35] |
Guo Y, Zou J, Xu X F, et al. Short-chain fatty acids combined with intronic DNA methylation of HIF3A: potential predictors for diabetic cardiomyopathy. Clinical Nutrition (Edinburgh, Scotland), 2021, 40(6):3708-3717.
doi: 10.1016/j.clnu.2021.04.007
|
[36] |
Vallianou N G, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones(Athens), 2019, 18(2):141-144.
|
[37] |
Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Reviews in Endocrine and Metabolic Disorders, 2019, 20(4):461-472.
doi: 10.1007/s11154-019-09512-0
pmid: 31707624
|
[38] |
Zhao L P, Zhang F, Ding X Y, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science, 2018, 359(6380):1151-1156.
doi: 10.1126/science.aao5774
|
[39] |
Tirosh A, Calay E S, Tuncman G, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Science Translational Medicine, 2019, 11(489): eaav0120.
|
[40] |
Perry R J, Peng L, Barry N A, et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature, 2016, 534(7606):213-217.
doi: 10.1038/nature18309
|
[41] |
Wu L W, Feng J, Li J J, et al. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomedicine & Pharmacotherapy, 2021, 133:111036.
doi: 10.1016/j.biopha.2020.111036
|
[42] |
Yehualashet A S, Yikna B B. Microbial ecosystem in diabetes mellitus: consideration of the gastrointestinal system. Diabetes, Metabolic Syndrome and Obesity, 2021, 14:1841-1854.
|
[43] |
Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends in Molecular Medicine, 2015, 21(11):702-714.
doi: S1471-4914(15)00175-6
pmid: 26481828
|
[44] |
Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, et al. The role of the gut microbiota in bile acid metabolism. Annals of Hepatology, 2017, 16(Suppl. 1: s3-105.):15-20.
doi: 10.5604/01.3001.0010.5494
pmid: 29080339
|
[45] |
Zheng X J, Chen T L, Jiang R Q, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metabolism, 2021, 33(4):791-803, e7.
doi: 10.1016/j.cmet.2020.11.017
|
[46] |
Kuang J L, Zheng X J, Huang F J, et al. Anti-adipogenic effect of theabrownin is mediated by bile acid alternative synthesis via gut microbiota remodeling. Metabolites, 2020, 10(11):475.
doi: 10.3390/metabo10110475
|
[47] |
Zhang B, Chen Y, Shi X L, et al. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma. Cellular and Molecular Life Sciences: CMLS, 2021, 78(1):195-206.
doi: 10.1007/s00018-020-03483-1
|
[48] |
Tian J, Liu C, Zheng X, et al. Porphyromonas gingivalis induces insulin resistance by increasing BCAA levels in mice. Journal of Dental Research, 2020, 99(7):839-846.
doi: 10.1177/0022034520911037
pmid: 32176550
|
[49] |
Eslami M, Bahar A, Hemati M, et al. Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders. Diabetic Medicine: a journal of the British Diabetic Association, 2021, 38(2):e14415.
|
[50] |
Allin K H, Nielsen T, Pedersen O. Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. European Journal of Endocrinology, 2015, 172(4):R167-R177.
doi: 10.1530/EJE-14-0874
|
[51] |
Saad M J A, Santos A, Prada P O. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda, Md), 2016, 31(4):283-293.
|
[52] |
Fassarella M, Blaak E E, Penders J, et al. Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. Gut, 2021, 70(3):595-605.
doi: 10.1136/gutjnl-2020-321747
pmid: 33051190
|
[53] |
Li X X, Zhang X X, Zhang R, et al. Gut modulation based anti-diabetic effects of carboxymethylated wheat bran dietary fiber in high-fat diet/streptozotocin-induced diabetic mice and their potential mechanisms. Food and Chemical Toxicology, 2021, 152:112235.
doi: 10.1016/j.fct.2021.112235
|
[54] |
Kovatcheva-Datchary P, Nilsson A, Akrami R, et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metabolism, 2015, 22(6):971-982.
doi: 10.1016/j.cmet.2015.10.001
pmid: 26552345
|
[55] |
Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annual Review of Physiology, 2019, 81:139-164.
doi: 10.1146/physiol.2019.81.issue-1
|
[56] |
Cummings N E, Williams E M, Kasza I, et al. Restoration of metabolic health by decreased consumption of branched-chain amino acids. The Journal of Physiology, 2018, 596(4):623-645.
doi: 10.1113/JP275075
pmid: 29266268
|
[57] |
Liu R X, Hong J, Xu X Q, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nature Medicine, 2017, 23(7):859-868.
doi: 10.1038/nm.4358
|
[58] |
Tiderencel K A, Hutcheon D A, Ziegler J. Probiotics for the treatment of type 2 diabetes: a review of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2020, 36(1):e3213.
|
[59] |
Salgaço M K, Oliveira L G S, Costa G N, et al. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Applied Microbiology and Biotechnology, 2019, 103(23-24):9229-9238.
doi: 10.1007/s00253-019-10156-y
pmid: 31664483
|
[60] |
Rena G, Hardie D G, Pearson E R. The mechanisms of action of metformin. Diabetologia, 2017, 60(9):1577-1585.
doi: 10.1007/s00125-017-4342-z
|
[61] |
Duca F A, Côté C D, Rasmussen B A, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Medicine, 2015, 21(5):506-511.
doi: 10.1038/nm.3787
|
[62] |
Maniar K, Moideen A, Mittal A, et al. A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: genesis of a wonder drug? Pharmacological Research, 2017, 117:103-128.
doi: S1043-6618(16)30954-9
pmid: 27939359
|
[63] |
Sun L L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nature Medicine, 2018, 24(12):1919-1929.
doi: 10.1038/s41591-018-0222-4
|
[64] |
Wu J Y, Wang K, Wang X M, et al. The role of the gut microbiome and its metabolites in metabolic diseases. Protein & Cell, 2021, 12(5):360-373.
|
[65] |
Bryrup T, Thomsen C W, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia, 2019, 62(6):1024-1035.
doi: 10.1007/s00125-019-4848-7
|
[66] |
Lee H, Lee Y, Kim J, et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. Gut Microbes, 2018, 9(2):155-165.
doi: 10.1080/19490976.2017.1405209
|
[67] |
Shin N R, Lee J C, Lee H Y, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 2014, 63(5):727-735.
doi: 10.1136/gutjnl-2012-303839
|
[68] |
Dimitrov D, Thiele I, Ferguson L R. Editorial: the human gutome: nutrigenomics of host-microbiome interactions. Frontiers in Genetics, 2016, 7:158.
doi: 10.3389/fgene.2016.00158
pmid: 27656194
|
[69] |
Zhang M C, Feng R L, Yang M, et al. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Research & Care, 2019, 7(1):e000717.
doi: 10.1136/bmjdrc-2019-000717
|
[70] |
Zhang X Y, Fang Z W, Zhang C F, et al. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial. Diabetes Therapy, 2017, 8(2):293-307.
doi: 10.1007/s13300-017-0226-y
|
[71] |
Cao T T B, Wu K C, Hsu J L, et al. Effects of non-insulin anti-hyperglycemic agents on gut microbiota: a systematic review on human and animal studies. Frontiers in Endocrinology (Lausanne), 2020, 11:573891.
|
[72] |
Smith B J, Miller R A, Ericsson A C, et al. Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. BMC Microbiology, 2019, 19(1):130.
doi: 10.1186/s12866-019-1494-7
|
[73] |
Gu Y Y, Wang X K, Li J H, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nature Communications, 2017, 8(1):1785.
doi: 10.1038/s41467-017-01682-2
|
[74] |
Li Y Q, Han L, Xu M, et al. The primary research on the gut microbes in KKAy mice. Indian Journal of Microbiology, 2014, 54(1):12-19.
doi: 10.1007/s12088-013-0410-3
|
[75] |
Olivares M, Neyrinck A M, Pötgens S A, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia, 2018, 61(8):1838-1848.
doi: 10.1007/s00125-018-4647-6
pmid: 29797022
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|